AGB101 for Preclinical Alzheimer's Disease

What Is This Study About?

AGB101 is an extended-release, low-dose preparation of levetiracetam, a drug approved by the U.S. Food and Drug Administration to treat certain types of seizures. It works by decreasing abnormal excitement in the brain. In this study researchers are investigating whether the drug can reduce abnormal brain activity and improve memory. Participants will be randomly assigned to take a capsule of the study drug or a placebo once daily for two weeks. After a four-week washout period (i.e., not taking the study drug or placebo), participants will rotate groups and take either the study drug or a placebo for another two weeks.

Do I Qualify To Participate in This Study?

Must have:

• Fluent in English
• At least eight years of education
• Geriatric Depression Scale score less than 6
• Hachinski Ischemic Score of 4 or less
• Normal general cognitive function and normal memory function, as determined by cognitive assessments

Must NOT have:

• Neurological disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis
• History of significant head trauma or known structural brain abnormalities
• Major psychiatric disease or chronic unstable medical conditions
• History of drug abuse
• History of alcohol abuse (four or more drinks per day on average)
• Unable to complete magnetic resonance imaging scans (e.g., pacemaker/defibrillator)
• Significant abnormalities in B12 or thyroid function tests
• End-stage renal disease
• Dialysis

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Where Is This Study Located?

Who Sponsors This Study?

Lead: Medical College of Wisconsin

Collaborator Sponsor

• National Institute on Aging (NIA)

Source: ClinicalTrials.gov ID: NCT03461861